Listed on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) in 1995, Wang On Group Limited ("Wang On Group") (stock code: 1222) is principally engaged in business activities comprising property development and investment, wet market management, pharmaceutical business, financial business and other investment. The Group has now developed into a leading conglomerate, with operations in Hong Kong and mainland China.

The Group has been actively involved in the local property market with luxury and boutique residential projects. Wang On Properties Limited (stock code: 1243) spun off from Wang On Group and became listed on SEHK since 2016. Its residential development projects include luxury residential projects "Meister House" and "Godi", as well as boutique residential properties under “The Met.” Series. In respect of property investment, the Group developed Ginza-style commercial properties under “LADDER” Series and acquired existing properties for sale or for leasing and holding as long-term investment, thereby diversifying its business.

Since 1996, the Group has further diversified its business by actively engaging in Chinese wet market and property management. The Group has established a new-generation Chinese wet market brand “Allmart”, which offers quality, convenient and hygienic shopping experience through its bright, clean and comfortable shopping environments. Being one of the largest leasing operators of Chinese wet markets in Hong Kong, the Group has also introduced a modernised operation model to mainland China. Leveraging the management’s extensive experience, the Group has successfully established a wet market management model under “Huimin” brand.

The Group has also successfully tapped into the lucrative pharmaceutical sector. Between 2001 and 2003, the Group acquired two renowned pharmaceutical brands, namely Wai Yuen Tong and Madame Pearl's. With an aim to create synergistic effect, the operations of the two brands were grouped under Wai Yuen Tong Medicine Holdings Limited (stock code: 897), which was subsequently listed. Pharmaceutical and healthcare products of the two brands are now sold in Hong Kong, Southeast Asia, Europe and America. The Group strives to enlarge its market share through diversifying its global business. Meanwhile, the Group has actively developed e-commerce to provide convenience to its customers, by lining up physical store and online platform, to strengthen the interaction with customers and create mutual benefits to the Group and its customers. In addition, the Group invested HK$600 million to construct a new five-storey factory in Yuen Long with production lines of both western pharmaceutical and Chinese traditional medicines. The new factory is expected to commence operation in 2017. The factory was awarded “Good Manufacturing Practice” issued by the Chinese Medicine Council of Hong Kong and the PIC/S Guide to Good Manufacturing Practice (GMP) for Medicinal Products issued by the Therapeutic Goods Administration (TGA) of Australia. The certifications help to enhance customer’s confidence and strengthen Wai Yuen Tong’s leading position in the market.

In addition, the Group also takes proactive measures to develop its financial services business, which currently offers a comprehensive range of services including corporate finance, mergers and acquisitions, etc. Led by experienced management with industry expertise, this business segment provides one‐stop investment service to individuals and corporate clients.

Our flexible and experienced management team will continue to strengthen our businesses by adopting a prudent yet forward-looking investment approach. They are committed to steering the Group to achieve sustainable development, strengthening the Group’s reputation that has been established over the years, as well as pursuing further diversification and internationalization of the Group’s businesses.